Bausch Health’s sales were constrained by the Covid-19 pandemic but the global consumer and international prescription activities of its Bausch + Lomb eye care division posted strong growth. It expects a recovery from the latter part of the second quarter but nevertheless cut its full-year guidance.
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.